Figures
In Fig 4, the statistical significance indicators are missing. Please see the corrected Fig 4 here.
(A) H3K27me3 enrichment in the MEOX2 promoter sequence (**Mann-Whitney U test, p≤0.01, and F test, p≤0.0003) and (B) H3K27me3 enrichment in the TWIST1 promoter sequence in high survival patients as compared to patients with poor prognoses (***Mann-Whitney U test,p≤0.01, and unpaired t-test, p≤0.02). (C) H3K27ac enrichment in the promoter sequence of MEOX2 (no significant changes) and (D) H3K27ac enrichment in the promoter sequence of TWIST1 in high survival patients compared to patients with poor prognoses (no significant changes). (E) H3K4me3 enrichment in the MEOX2 promoter sequence (*F test, p≤0.02) and (F) the TWIST1 promoter sequence in high survival patients compared to patients with poor prognoses (***F test, p≤0.0006). Error bars represent mean with range.
Reference
Citation: Ávila-Moreno F, Armas-López L, Álvarez-Moran AM, López-Bujanda Z, Ortiz-Quintero B, Hidalgo-Miranda A, et al. (2016) Correction: Overexpression of MEOX2 and TWIST1 is Associated with H3K27me3 Levels and Determines Lung Cancer Chemoresistance and Prognosis. PLoS ONE 11(2): e0146569. https://doi.org/10.1371/journal.pone.0146569
Published: February 10, 2016
Copyright: © 2016 Ávila-Moreno et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited